Core Insights - CS Diagnostics Corp. has confirmed strategic manufacturing partnerships with Emirate Wet Wipes LLC and Gulf Centre Group Factory to accelerate the commercial production of its MEDUSA SDP product line, which includes medical-grade wet wipes and liquid disinfectants [1][3][4] Group 1: Manufacturing Partnerships - Emirate Wet Wipes LLC will manufacture the MEDUSA SDP disinfectant wet wipes, while Gulf Centre Group Factory will produce bulk liquid hygiene formulations in various sizes [3] - These partnerships ensure scalable manufacturing capacity, quality-controlled production, and compliance with health and safety standards, facilitating distribution across hospitals, clinics, retail chains, and e-commerce platforms [3][4] Group 2: Commercialization Milestone - Securing these manufacturing partners is a significant milestone for CS Diagnostics, transitioning MEDUSA SDP from development to revenue-ready production [4][6] - The partnerships enable the company to meet global demand and maintain operational flexibility as it expands into infection control and medical sanitation markets [4][6] Group 3: Market Demand and Trends - MEDUSA SDP is designed to meet the increasing demand for infection prevention solutions and everyday hygiene products, aligning with long-term healthcare spending trends and regulatory focus on sanitation and public health [5][6] - The company aims to deliver scalable, compliant, and medically trusted products across various markets, including healthcare and consumer sectors [6][7] Group 4: Future Plans - CS Diagnostics is progressing through key commercialization milestones, including international launches and diversified distribution channels [7][8] - The company plans to introduce biodegradable hygiene products and expand its presence in global markets [8]

CHEYENNE, Wyo., Jan. 21, 2026 (GLOBE NEWSWIRE) -- CS Diagnostics Corp. (OTCQB: CSDX) today detailed its multi-channel sales strategy, global logistics partnerships, and sustainability roadmap supporting the commercial rollout of MEDUSA SDP. The Company plans to distribute MEDUSA SDP through a diversified sales model designed to serve both institutional and consumer demand. B2B distribution channels include: Hospitals and healthcare facilitiesGyms and wellness centersSchools and educational institutionsCorp ...

Core Insights - CS Diagnostics Corp. (CSDX) is launching a multi-channel sales strategy for its MEDUSA SDP product, focusing on both institutional and consumer markets [1][2]. Sales Strategy - The company plans to utilize a diversified sales model that includes B2B and B2C distribution channels [2]. - B2B distribution channels will target hospitals, healthcare facilities, gyms, wellness centers, schools, corporate clients, and industrial clients [4]. - B2C channels will include physical retail stores in the UAE and Germany, online marketplaces like Amazon and Noon, and direct-to-consumer sales via the official MEDUSA e-commerce website [4]. Logistics and Sustainability - DHL has been selected for bulk and institutional shipments, while FedEx will handle retail and consumer deliveries [6]. - The company is also pursuing regulatory approval for a biodegradable, dissolving line of MEDUSA SDP wet wipes, which aligns with its sustainability roadmap [6]. Company Overview - CS Diagnostics Corp. is a medical technology company focused on infection control and oncology, with products including the MEDUSA platform and CS Protect-Hydrogel [8]. - The company is advancing through key commercialization milestones, including strategic manufacturing partnerships and multi-region launches across the GCC and Europe [8]. - Plans for future product introductions include biodegradable hygiene products and international expansion [8].